Clinical Trial Update: A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal [Phase 2]

View source ↗

Summary

Phase 2 study of Axalimogene Filolisbac (ADXS11-001) in anorectal canal carcinoma completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Rectal Cancer

Drugs mentioned

• Axalimogene filolisbac (Axalimogene filolisbac)

Snippet

Sponsor: Advaxis, Inc. | Conditions: Anal Cancer, Rectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-03-20